An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations - PubMed

Practice Guideline

An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations

Ritu Salani et al. Gynecol Oncol. 2017 Jul.

Abstract

Gynecologic cancers account for ~12% of all new cancer cases in women and ~15% of all female cancer survivors. Current and continued advances within the field have resulted in long-term outcomes and a high rate of survivors. Therefore determining the most cost-effective clinical surveillance for detection of recurrence is critical. Unfortunately, there has been a paucity of research regarding the most effective strategies for surveillance after patients have achieved a complete response. Currently, most recommendations are based on retrospective studies and expert opinion. Taking a thorough history, performing a thorough examination, and educating cancer survivors about concerning symptoms are the most effective methods for the detection of most gynecologic cancer recurrences. There is very little evidence that routine cytology or imaging improves the ability to detect gynecologic cancer recurrence that will impact cure or response rates to salvage therapy. This article provides an update on surveillance for gynecologic cancer recurrence in women who have had a complete response to primary cancer therapy.

Keywords: Cytology; Gynecologic cancer; Imaging; Pap test; Surveillance; Tumor markers.

Similar articles

• Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.

  Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE, Goff BA. Salani R, et al. Am J Obstet Gynecol. 2011 Jun;204(6):466-78. doi: 10.1016/j.ajog.2011.03.008. Am J Obstet Gynecol. 2011. PMID: 21752752 Review.

• Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice.

  Rimel BJ, Burke WM, Higgins RV, Lee PS, Lutman CV, Parker L. Rimel BJ, et al. Gynecol Oncol. 2015 May;137(2):280-4. doi: 10.1016/j.ygyno.2015.02.021. Epub 2015 Feb 28. Gynecol Oncol. 2015. PMID: 25735256

• Recommendations for Follow-up Care for Gynecologic Cancer Survivors.

  Elit L, Reade CJ. Elit L, et al. Obstet Gynecol. 2015 Dec;126(6):1207-1214. doi: 10.1097/AOG.0000000000001129. Obstet Gynecol. 2015. PMID: 26551194 Review.

• Positron Emission Tomography/Computed Tomography for Gynecologic Malignancies.

  Oldan JD, Patel PS. Oldan JD, et al. Obstet Gynecol Surv. 2016 Sep;71(9):545-56. doi: 10.1097/OGX.0000000000000345. Obstet Gynecol Surv. 2016. PMID: 27640609 Review.

• [Value of colposcopy in diagnosing recurrent gynecologic malignancies].

  Zhang WH. Zhang WH. Zhonghua Zhong Liu Za Zhi. 1990 Nov;12(6):438-40. Zhonghua Zhong Liu Za Zhi. 1990. PMID: 2076640 Chinese.

Cited by

• The Roles of Autophagy-related miRNAs in Gynecologic Tumors: A Review of Current Knowledge for Possible Targeted Therapy.

  Mobinikhaledi M, Faridzadeh A, Farkhondeh T, Pourhanifeh MH, Samarghandian S. Mobinikhaledi M, et al. Curr Mol Med. 2024;24(10):1269-1281. doi: 10.2174/0115665240263059231002093454. Curr Mol Med. 2024. PMID: 39300715 Review.

• Prevalence and Risk Factors of Low Anterior Resection Syndrome in Epithelial Ovarian Cancer Surgery.

  Yasin I, Saeed Usmani A, Mohsin J, Asif RB, Kahlid N, Syed AA. Yasin I, et al. Cureus. 2022 Mar 15;14(3):e23180. doi: 10.7759/cureus.23180. eCollection 2022 Mar. Cureus. 2022. PMID: 35444906 Free PMC article.

• Prognostic Effect of Primary Recurrence Patterns in Squamous Cervical Carcinoma After Radical Surgery.

  Zhang Z, Jiang L, Bi R, Wu X, Ke G, Zhu J. Zhang Z, et al. Front Oncol. 2022 Apr 11;12:782030. doi: 10.3389/fonc.2022.782030. eCollection 2022. Front Oncol. 2022. PMID: 35480094 Free PMC article.

• External validation study of endometrial cancer preoperative risk stratification model (ENDORISK).

  Vinklerová P, Ovesná P, Hausnerová J, Pijnenborg JMA, Lucas PJF, Reijnen C, Vrede S, Weinberger V. Vinklerová P, et al. Front Oncol. 2022 Aug 3;12:939226. doi: 10.3389/fonc.2022.939226. eCollection 2022. Front Oncol. 2022. PMID: 35992828 Free PMC article.

• Comparison of recurrence patterns in cervical cancer patients with positive lymph nodes versus negative.

  Ji M, Liu Y, Hu Y, Sun J, Zhu H. Ji M, et al. Cancer Med. 2023 Jan;12(1):306-314. doi: 10.1002/cam4.4860. Epub 2022 May 26. Cancer Med. 2023. PMID: 35616316 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program